IDEXX

Q3 2026
Speakers

Nov 2, 2026 · 57 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good morning and welcome to the IDEX Laboratory's third quarter 2026 earnings conference call. As a reminder, today's conference is being recorded. Participating in the call this morning are Mike Erickson, President and Chief Executive Officer, Andrew Emerson, Chief Financial Officer, and John Ravis, Vice President Investor Relations. IDEX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today.

Additional information regarding these risks and uncertainties
is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the investor relations section of our website, IDEX.com. During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP.

A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is provided in our earnings release, which may also be found by visiting the Investor Relations section of our website. In reviewing our third quarter 2026 results and updated
2026 guidance, please note all references to growth, organic growth, and comparable growth refer to growth compared to the equivalent prior year period unless otherwise To allow broad participation in the QA, we ask that each participant limit their questions to one with one follow-up as necessary.

We appreciate you may have
additional questions, so please feel free to get back into the queue and if time permits, we'll take your additional questions. Today's prepared remarks will be posted to the investor relations section of our website after the earnings conference call concludes. I would now like to turn the call over to Andrew Emerson.

Passages & reports (6)
  • Good morning and welcome to the IDEX Laboratory's third quarter 2026 earnings conference c…
  • Relations. IDEX would like to preface the discussion today with a caution regarding forwar…
  • is available under the forward-looking statements notice in our press release issued this …
  • not prepared in accordance with generally accepted accounting principles or GAAP. A reconc…
  • 2026 guidance, please note all references to growth, organic growth, and comparable growth…
  • additional questions, so please feel free to get back into the queue and if time permits, …

Speaker unclear

?Good

Passages & reports (1)
  • Good

Speaker 1

Unverified voice label

morning. I'm pleased to take you through our third quarter results and provide an updated outlook for our full year 2026 financial expectations. During the third quarter, ?IDEX delivered outstanding financial results, driven by strong global execution, the expanding impact of IDEX innovations, and continued progress in increasing the medically relevant use of diagnostics across our companion animal business. We also advanced our software, data, and AI capabilities through the acquisition of COVID.

Revenue increased 10% organically, supported by 11% organic growth in CAG diagnostics recurring revenues, reflecting nearly 14% gains in international regions and nearly 10% growth in the US. We see strong demand for diagnostic solutions, including IDEX innovations as
demonstrated with premium instrument placements of nearly 5,800 units, with over 1,900 IDEX NVDX analyzers. Operating performance was excellent, with comparable operating margin gains of approximately 60 basis points year over year, led by improvement in gross margin while making ongoing investments in the business, including costs related to the COVID acquisition.

Strong operating profit gains enabled earnings per share of $4.01 and the quarter, an increase of 18% as reported, and 22% on a comparable basis. Strong third quarter performance supports an increase to our full year revenue outlook.

Passages & reports (6)
  • morning. I'm pleased to take you through our third quarter results and provide an updated …
  • IDEX
  • delivered outstanding financial results, driven by strong global execution, the expanding …
  • COVID. Revenue increased 10% organically, supported by 11% organic growth in CAG diagnosti…
  • demonstrated with premium instrument placements of nearly 5,800 units, with over 1,900 IDE…
  • including costs related to the COVID acquisition. Strong operating profit gains enabled ea…

We are raising our full year revenue range to $4,741,000 to billion seven hundred and sixty seven million, an increase of thirty two million dollars at midpoint, reflecting strong third quarter performance and approximately five million dollars of revenue from COVID. Our updated full year overall organic revenue growth outlook is nine point three percent to ten percent, with organic CAG diagnostics recurring revenue growth of ten point three percent to eleven percent.

These ranges represent an increase of approximately sixty basis points at midpoint, along with tightening the low end of the range as we enter the final
quarter of the year. We also increased our full year EPS outlook to $14.96 to $15.16 per share, an increase of 25 cents per share at midpoint, reflecting 15% to 16% comparable EPS growth while observing near-term dilution related to the COVID acquisition.

We'll provide further details on on our updated 2026 financial expectations later in my comments. Let's begin with a review of our third quarter results. Third quarter organic revenue growth of 10% was driven by 10% CAG revenue gains, 8%
growth in our water business, and 3% growth in LPD. Strong CAG results were driven by CAG diagnostics recurring revenue growth of 11% organically, which was volume-led, reflecting strong execution and contributions from innovations, and included approximately 4% global net price improvement.

Passages & reports (5)
  • We are raising our full year revenue range to $4,741,000 to billion seven hundred and sixt…
  • revenue growth outlook is nine point three percent to ten percent, with organic CAG diagno…
  • quarter of the year. We also increased our full year EPS outlook to $14.96 to $15.16 per s…
  • observing near-term dilution related to the COVID acquisition. We'll provide further detai…
  • growth in our water business, and 3% growth in LPD. Strong CAG results were driven by CAG …

Demand for IDEX diagnostic solutions remains high, and we've realized benefits from net new customer gains, expansion of our premium instrument install base, and increased utilization of IDEX innovations. U.S. organic CAG diagnostics recurring revenue grew 9.6% in Q3, with solid volume gains and net price realization aligned with our full year expectations. U.S. growth continues to be supported by greater testing frequency and intensity per visit as customers adopt our expanded menu.

U.S. same-store clinical visits declined an estimated 1.8% in the quarter,
reflecting a U.S. CAG diagnostics recurring revenue growth premium of approximately eleven hundred basis points, our fourth consecutive quarter above a thousand basis points. Underlying patient dynamics continue to support long-term demand for diagnostics. ?In the quarter, pets aged five plus years, where diagnostic frequency rises contributed to clinical visit growth. With a substantial majority of wellness visits still not including blood work, increased diagnostic inclusion remains a long duration growth lever that does not depend on visit growth.

International CAG diagnostic recurring revenues grew fourteen percent organically in Q three, with double digit gains across major international regions. International performance reflects the success of our strategic focus on developing the sector and strong IDEX execution. We're also encouraged by the quality of
growth reflected by the strong momentum in net new customers and same store sales gains. We've successfully completed expansions highlighted on the second quarter call well ahead of schedule.

IDEX innovation and commercial execution drove strong organic revenue gains across our major testing modalities
globally in the quarter. IDEX VETLAB consumable revenues increased 15% on an organic basis, reflecting double-digit growth in both the U.S. and international regions. Consumables growth was supported by the expansion of our premium instrument install base and broader menu utilization.

Passages & reports (8)
  • Demand for IDEX diagnostic solutions remains high, and we've realized benefits from net ne…
  • with solid volume gains and net price realization aligned with our full year expectations.…
  • reflecting a U.S. CAG diagnostics recurring revenue growth premium of approximately eleven…
  • In
  • the quarter, pets aged five plus years, where diagnostic frequency rises contributed to cl…
  • International CAG diagnostic recurring revenues grew fourteen percent organically in Q thr…
  • growth reflected by the strong momentum in net new customers and same store sales gains. W…
  • globally in the quarter. IDEX VETLAB consumable revenues increased 15% on an organic basis…

We benefited from ongoing growth of catalyst pancreatic lipase, catalyst cortisol, and SDMA inclusion and chemistry runs following the integration of SDMA into our chemistry clips. MVUDX reoccurring revenue continues to ramp, aided by the expanding install base and broadening of FNA on the platform. We remain in our estimated range of 3,500 to 5,500 of recurring revenue per analyzer while making fine needle aspirate testing with canine mass cell termodetection available across all North America customers at the beginning of Q4.

Premium
instrument placements reached 5,780 units in the quarter, and placement quality remained high. Globally, we placed 1,904 MUDX instruments with strong international demand and nearly 1,200 competitive and greenfield catalyst placements globally, with over 300 in the US. IDEC's global reference lab revenues increased 10% organically in Q3, led by volume gains from net new customers, including competitive lab wins in the U.S., and increased same store utilization as customers adopt broader testing menu. ?

The
IDEX Cancer DX customer base continued to expand, with nearly a quarter of customers ordering in Q3 representing nonprimary IDEX reference lab accounts. With the addition of canine mast cell tumor detection to the panel in late September, we've meaningfully increased the medical value to customers without increasing our price on the panel. Global rapid assay revenues increased 1% organically in Q3, sustaining modest growth seen during Q2.

Veterinary, software, and diagnostic imaging organic revenues increased 10%, driven by recurring revenue growth and strong placements of our DR
50 plus platform, including another record quarter of installations in the U.S. Our cloud native PIMS footprint continues to expand across both independent and corporate owned clinics as ?well. In September, we acquired COVET, a leading and rapidly growing provider of AI native ambient listening and clinical workflow software for veterinary practices. ?

The
COVET revenue run rate is approximately $20 million annualized and growing at strong double-digit rates, creating another revenue growth driver for the software modality and opportunity for further supporting diagnostic utilization. Water revenues increased 8% organically in Q3, and livestock poultry and dairy revenues increased 3% organically. Turning to the PL, strong recurring revenue growth enabled 13% reported operating profit gains with reported operating margins of 33.1%, up 100 basis points as reported, and approximately 60 basis points on a comparable basis, inclusive of COVID-related costs.

Gross profit increased 12% in the quarter as reported, and gross margins were 62.9%, up 110 basis points as reported, and 90 basis points on a comparable basis. These gains reflect benefits from
strong recurring revenue growth in IDEX VET lab consumables and reference lab volumes, operational productivity, and favorable product mix with pricing benefits offsetting inflationary cost pressures. On a reported basis, operating expenses increased 10% year over year and 11% on a comparable basis, including COVID related costs.

We continue to advance investments in our innovation agenda, global commercial expansions, and information technology capabilities. Q3 EPS was $4.01 per share, an increase of 18% as reported and 22% on a comparable basis.

Passages & reports (16)
  • We benefited from ongoing growth of catalyst pancreatic lipase, catalyst cortisol, and SDM…
  • FNA on the platform. We remain in our estimated range of 3,500 to 5,500 of recurring reven…
  • instrument placements reached 5,780 units in the quarter, and placement quality remained h…
  • over 300 in the US. IDEC's global reference lab revenues increased 10% organically in Q3, …
  • The
  • IDEX Cancer DX customer base continued to expand, with nearly a quarter of customers order…
  • increasing our price on the panel. Global rapid assay revenues increased 1% organically in…
  • 50 plus platform, including another record quarter of installations in the U.S. Our cloud …
  • well.
  • In September, we acquired COVET, a leading and rapidly growing provider of AI native ambie…
  • The
  • COVET revenue run rate is approximately $20 million annualized and growing at strong doubl…
  • and livestock poultry and dairy revenues increased 3% organically. Turning to the PL, stro…
  • points on a comparable basis, inclusive of COVID-related costs. Gross profit increased 12%…
  • strong recurring revenue growth in IDEX VET lab consumables and reference lab volumes, ope…
  • including COVID related costs. We continue to advance investments in our innovation agenda…

EPS in the quarter included a 3 cent per share benefit related to a $3.5 million non-operating gain on an equity investment, bringing the year-to-date benefit to $0.50 per share or $4.7 million. Share based compensation activity benefited the quarter by one cent per share, compared to a $17 cent per share benefit in the prior year period, and foreign exchange added $4 million to operating profit and four cents to EPS in Q3 net of hedge effects.

Free cash flow was four hundred and twenty-one million dollars in Q3 and $978 million dollars year to date. On
a trailing twelve month basis, our net income to free cash flow conversion rate was one hundred and ten percent. ?For the full year, our updated outlook for free cash flow conversion is ninety five percent to one hundred percent of net income, including updated full year capital spending of approximately one hundred and sixty million dollars.

Our balance sheet remains strong. Total debt was aligned with prior year end as strong free cash flow supported
repaying seventy five million dollars of senior notes in the quarter, and we deployed approximately $335 million of capital towards the COVID acquisition and share repurchases in Q3, bringing the year-to-date share repurchases to $805 million, and supporting a 2% year-over-year reduction in diluted shares outstanding.

Turning to our full year 2026 outlook, as noted, we're increasing our outlook for overall revenue to $4,741 million to hundred and sixty seven million dollars, an increase of thirty two million dollars at midpoint. This reflects the flow-through
benefits of strong third quarter performance, COVET revenue, and relatively consistent foreign exchange effects compared to prior estimates. Our reported revenue growth of ten point one percent to ten point eight percent includes approximately seventy basis points benefit from foreign exchange at the rates outlined in our press release and approximately five million dollars of COVID revenue in 2026.

As a sensitivity, a 1% strengthening of the US dollar would reduce revenue by approximately $4 million and EPS by 2 cents per share for the remainder of the year. Our updated overall organic revenue growth
outlook of 9.3% to 10% includes organic growth range of 10.3% to 11% for CAG diagnostics recurring revenue, including approximately 4% benefit from global net price realization. Momentum across our innovation portfolio, including recent launches of CALUS ProBMP, broadening of Inview DX FNA, and the expanded Cancer DX panel, together with our larger global commercial footprint, supports our outlook. ?

In
terms of key financial metrics, we're updating our reported operating margin outlook to 32.1% to 32.3% for 2026, reflecting 50 to 70 basis points of full year comparable operating margin improvement. ?The updated outlook includes approximately 30 basis points of negative impact related to COVID, including integration costs and one quarter of estimated amortization. We expect to expand margin off of these levels over the next 12 months, aligned with our long-term goals.

Our updated full year EPS outlook is
14.96 to $15.16 per share, an increase of 25 cents per share at midpoint. This reflects approximately 12 cents per share improvement in our operational outlook, along with benefits from a lower effective tax rate, now estimated at 20.5%, lower net interest expense of approximately $32 million, and $0.50 per share benefit from non operating gain on an equity investment, partially offset by approximately $13 per share of dilution related to COVID.

Full year foreign exchange benefits EPS by approximately 25 cents per share rates outlined in our
press release, and our outlook continues to include $19 million or 24 cents per share of share based compensation benefits and a 2% reduction in average diluted shares outstanding. For the fourth quarter, our implied reported revenue growth range includes an approximately 70 basis point headwind from foreign currency, partially offset by benefits from the COVID acquisition.

We expect reported operating margins of 28.4% to 29.3% in the quarter, which benefits from gross margin improvement being offset by COVID expenses and ongoing investments in the business.

Passages & reports (19)
  • EPS in the quarter included a 3 cent per share benefit related to a $3.5 million non-opera…
  • compared to a $17 cent per share benefit in the prior year period, and foreign exchange ad…
  • a trailing twelve month basis, our net income to free cash flow conversion rate was one hu…
  • For
  • the full year, our updated outlook for free cash flow conversion is ninety five percent to…
  • repaying seventy five million dollars of senior notes in the quarter, and we deployed appr…
  • outstanding. Turning to our full year 2026 outlook, as noted, we're increasing our outlook…
  • benefits of strong third quarter performance, COVET revenue, and relatively consistent for…
  • release and approximately five million dollars of COVID revenue in 2026. As a sensitivity,…
  • outlook of 9.3% to 10% includes organic growth range of 10.3% to 11% for CAG diagnostics r…
  • launches of CALUS ProBMP, broadening of Inview DX FNA, and the expanded Cancer DX panel, t…
  • In
  • terms of key financial metrics, we're updating our reported operating margin outlook to 32…
  • The
  • updated outlook includes approximately 30 basis points of negative impact related to COVID…
  • 14.96 to $15.16 per share, an increase of 25 cents per share at midpoint. This reflects ap…
  • expense of approximately $32 million, and $0.50 per share benefit from non operating gain …
  • press release, and our outlook continues to include $19 million or 24 cents per share of s…
  • point headwind from foreign currency, partially offset by benefits from the COVID acquisit…

That concludes our financial review. I'll now turn the call over to Mike for his comments.

Passages & reports (1)
  • That concludes our financial review. I'll now turn the call over to Mike for his comments.

Speaker 2

Unverified voice label

Thank you, Andrew, and good morning. IDEX delivered an exceptional third quarter driven by execution across all growth drivers, expansion of diagnostic utilization, growth in our global instrument and customer base, and continued delivery against our broad-based innovation pipeline. Our innovations work together as a solution across point of care, reference labs, and software to expand care and diagnostics utilization in the hands of our customers.

IDEX diagnostics and software innovations are enabling more pets
around the world to get the high quality care they deserve. This morning I'll focus my comments on three areas global commercial execution, diagnostics and software innovation delivery, and our acquisition of COVID. Our commercial execution was strong again this quarter, reflected in exceptional instrument placements, new customer acquisition, and volume driven growth ahead of sector averages. ?

At
the point of care, each instrument placement is a long term platform investment by the practice, and every menu addition grows the recurring value of that installed base. Our reference labs delivered another quarter of double digit growth, led by volume expansion, including strong pull through from Cancer DX. And in diagnostic imaging, we delivered a third consecutive quarter of more than 300 digital radiography placements driven by demand for the DR 50 plus.

Customer retention in CAG diagnostics remains in the high
90s globally, reflecting the trust veterinarians place in IDEX and the durable value of our integrated solutions. We know from experience that diagnostics is a performance category. Practices that embrace our innovative platforms, point of care, reference labs, software and imaging see higher growth in both their diagnostics and overall practice revenue. Internationally, demand for IDEX innovations remains robust.

The commercial expansions we announced on the Q2 call for France, Spain, South Korea, and
Canada were all completed ahead of schedule. These investments follow our well proven playbook for accelerated sector development through smaller territories for increased customer proximity. When we work side by side with our customers to build our innovations into their everyday protocols, we see higher diagnostics adoption and utilization supporting practice growth.

Turning to innovation, MVUDX momentum is strong, and we're well on track to exceed our placement goal of 5,500 for the year. Nearly half of our Q3
placements were international, showing that the value of this paradigm changing platform resonates with clinicians around the world. We added both nucleated red blood cells and eccentricytes to blood morphology in Q3. These updates push automatically to our global installed base of nearly 11,000 in viewDX instruments with no action required by the practice. ?

At
the start of the fourth quarter, we opened fine needle aspirate or FNA availability to all North American NVUDX customers, and every new North American placement now includes FNA. Every day, veterinarians face dogs with suspicious lumps and bumps and a pet parent worried about cancer. Today, only around 10% of these masses get assessed because of the cost and the complexity of glass slides and sending samples ?out.

Early customers using FNA on InVUDX are evaluating twice as many masses. This is IDEX innovation, bending the cost curve to expand care access and care volume. We've also broadened what FNA can identify, adding lipomas and
keratinized growth alongside mast cell tumor detection. A mast cell tumor can feel very similar to a lipoma, which is why examining the cells matters. With InVUDX, veterinarians can give owners answers and reassurance during the visit and focus on the masses that need attention. ?

And
if a mass needs further evaluation, a board certified IDEX pathologist review is one click away, which also brings more volume to our reference labs. For customers not currently using our lab, InVUDX placements also include onboarding to the IDEX reference lab for a seamless Experience. IDEX Cancer DX continues to be one of our most important innovations, filling a critical gap in care for early and specific cancer detection.

Cancer is the top cause of mortality in dogs, with more than 25 million
at-risk dogs globally. Tragically, cancer is often found too late to take action. Early detection expands treatment options and has the potential to extend a pet's life. ?In the third quarter, we delivered another milestone, adding canine mast cell tumor detection alongside canine lymphoma in North America, taking cancer DX from a test to a multi-cancer panel.

Mast cell tumors are among the most common cancers in dogs
and are frequently missed. We tune detection toward the more aggressive forms where early detection makes the greatest difference and a positive result is highly actionable. Mast cell tumor detection also connects directly to NVUDX. A positive result for mast cell tumor on cancer DX prompts a next step to examine any external masses for cancer using NVUDX FNA.

This is the kind of connected solution IDEX can deliver across point of care and reference labs. As we shared at Investor Day, we're
offering the expanded Cancer DX panel at the same affordable price as when we launched, as low as $15 in the U.S., when run with most blood work panels in the IDEX reference labs. Doctors and pet parents should never have to choose between early cancer screening and wellness blood work.

These should be run together for at-risk dogs. Independent practices practices and corporate groups alike are welcoming our leadership stance on affordable screening. CancerDX runs on the same blood sample practices already send us for routine blood work, with no change to
specimen requirements or workflow. We see strong evidence that our strategy to grow blood work utilization is working. 70% of Cancer DX runs are part of a broader blood work panel, and customers who adopt Cancer DX see higher higher routine testing volumes. ?

By
the end of the year, Cancer DX capabilities will expand further to include hemangiosarcoma detection, and we are planning for broad customer availability in North America beginning in the first quarter. Hemangiosarcomas grow silently inside an organ like the spleen, and are too often discovered only as an emergency when the mass ruptures and the dog can be lost within hours. This is a heartbreaking experience for owners and veterinarians alike. ?

With
homangiosarcoma, Cancer DX will address approximately 40% of all canine cancers. We believe this marks a tipping point for affordable cancer screening, inspiring broader wellness blood work. Earlier this month, we also advanced our technology for life platform strategy with the North American launch of Catalyst Pro-BMP, the first and only dual species quantitative cardiac test at the point of care. Heart disease affects approximately one in six cats and one in ten dogs, yet it remains underassessed in general practice, with only about 420 veterinary cardiologists in the U.S.

for more than 23 million affected cats and dogs. Catalyst ProBMP supports screening,
diagnosis, and monitoring across multiple clinical scenarios. It delivers quantitative results during the patient visit with laboratory level accuracy, so decisions can be made while the patient is still in the clinic, and results appear in VecConnect Plus with built-in interpretive guidance. Catalyst menu additions, such as SDMA inclusive clips, pancreatic lipase, cortisol, and now ProBMP, expand the value of our over 80,000 catalysts around the world.

Passages & reports (40)
  • Thank you, Andrew, and good morning. IDEX delivered an exceptional third quarter driven by…
  • pipeline. Our innovations work together as a solution across point of care, reference labs…
  • around the world to get the high quality care they deserve. This morning I'll focus my com…
  • this quarter, reflected in exceptional instrument placements, new customer acquisition, an…
  • At
  • the point of care, each instrument placement is a long term platform investment by the pra…
  • strong pull through from Cancer DX. And in diagnostic imaging, we delivered a third consec…
  • 90s globally, reflecting the trust veterinarians place in IDEX and the durable value of ou…
  • labs, software and imaging see higher growth in both their diagnostics and overall practic…
  • Canada were all completed ahead of schedule. These investments follow our well proven play…
  • their everyday protocols, we see higher diagnostics adoption and utilization supporting pr…
  • placements were international, showing that the value of this paradigm changing platform r…
  • 11,000 in viewDX instruments with no action required by the practice.
  • At
  • the start of the fourth quarter, we opened fine needle aspirate or FNA availability to all…
  • parent worried about cancer. Today, only around 10% of these masses get assessed because o…
  • out.
  • Early customers using FNA on InVUDX are evaluating twice as many masses. This is IDEX inno…
  • keratinized growth alongside mast cell tumor detection. A mast cell tumor can feel very si…
  • attention.
  • And
  • if a mass needs further evaluation, a board certified IDEX pathologist review is one click…
  • seamless Experience. IDEX Cancer DX continues to be one of our most important innovations,…
  • at-risk dogs globally. Tragically, cancer is often found too late to take action. Early de…
  • In
  • the third quarter, we delivered another milestone, adding canine mast cell tumor detection…
  • and are frequently missed. We tune detection toward the more aggressive forms where early …
  • cell tumor on cancer DX prompts a next step to examine any external masses for cancer usin…
  • offering the expanded Cancer DX panel at the same affordable price as when we launched, as…
  • and wellness blood work. These should be run together for at-risk dogs. Independent practi…
  • specimen requirements or workflow. We see strong evidence that our strategy to grow blood …
  • By
  • the end of the year, Cancer DX capabilities will expand further to include hemangiosarcoma…
  • often discovered only as an emergency when the mass ruptures and the dog can be lost withi…
  • With
  • homangiosarcoma, Cancer DX will address approximately 40% of all canine cancers. We believ…
  • also advanced our technology for life platform strategy with the North American launch of …
  • one in ten dogs, yet it remains underassessed in general practice, with only about 420 vet…
  • diagnosis, and monitoring across multiple clinical scenarios. It delivers quantitative res…
  • interpretive guidance. Catalyst menu additions, such as SDMA inclusive clips, pancreatic l…

We've seen how software, data, and AI are powerful enablers of diagnostic utilization growth. And in September, we strengthened these capabilities with the acquisition of COVET, a leading AI clinical assistant purpose-built for veterinary practices. COVET gives time back to clinical teams and helps them deliver more complete care. When I visit practices, I see the friction firsthand. Complex caseloads, rising pet parent expectations, and burdensome documentation that pulls clinicians away from their patients.

COVET automatically captures exam room and phone conversations, builds treatment plans, and supports more personalized client follow-up after the visit. Every minute saved is capacity to see more patients, and in-context
prompts help with next steps. Practices and groups using COVET are seeing measurable gains in team productivity and satisfaction across the care workflow. With COVET, we saw a category leading solution along with a talented AI native team with deep sector knowledge.

COVET has rapidly grown adoption across the U.S. and more than a dozen countries internationally. Combined with IDEX's software, data, diagnostics, and commercial capabilities,
COVET advances our vision for an AI powered, connected system that unlocks greater value from information generated throughout the clinical workflow to support expanded patient care. COVET is already integrated with EasyVet, and we will integrate it more deeply with our other software and data assets, including VetConnect Plus and Velo.

We'll also continue to advance COVET integrations with non IDEX practice management systems. COVET's international footprint extends our software reach to
benefit customers in geographies not currently served by IDEX practice management systems. Looking ahead, I'm energized by the opportunity in front of ?us. The long term drivers of the animal health sector remain sound. The bond between people and their pets continues to deepen.

Pets are living longer and aging into the years when diagnostics matter most. Expectations for quality care keep rising with diagnostics at the
center of clinical decision making. These factors reinforce the durability of sector growth, while practices and corporate groups that embrace innovation and engage their clients realize faster growth. They're leaning into IDEX diagnostics and software as growth engines. Combined with IDEX execution, this is driving our growth well above sector averages.

We're in the early innings of a broad based innovation cycle. InVUDX and FNA, Cancer DX as a multi cancer panel,
Catalyst Pro BMP, COVET, and our software. Next up is IDEX MultiQDX, our next paradigm changing point of care platform designed and built here in Maine, USA. We'll share more at an investor event at VMX in Orlando on Monday, January 18th at 1 p.m.

Eastern. We'll also make this available via live stream on the investor relations section of our website.
?I hope you can join ?us. To IDEX employees around the world, thank ?you. And a special warm welcome to our new colleagues from COVET. Your commitment to innovations that help clinical teams see more and do more is what turns diagnostic and software innovation into long-term durable growth for our customers and for IDEX.

With that, I'll open the line for QA.

Passages & reports (21)
  • We've seen how software, data, and AI are powerful enablers of diagnostic utilization grow…
  • veterinary practices. COVET gives time back to clinical teams and helps them deliver more …
  • that pulls clinicians away from their patients. COVET automatically captures exam room and…
  • prompts help with next steps. Practices and groups using COVET are seeing measurable gains…
  • talented AI native team with deep sector knowledge. COVET has rapidly grown adoption acros…
  • COVET advances our vision for an AI powered, connected system that unlocks greater value f…
  • integrate it more deeply with our other software and data assets, including VetConnect Plu…
  • benefit customers in geographies not currently served by IDEX practice management systems.…
  • us.
  • The long term drivers of the animal health sector remain sound. The bond between people an…
  • center of clinical decision making. These factors reinforce the durability of sector growt…
  • engines. Combined with IDEX execution, this is driving our growth well above sector averag…
  • Catalyst Pro BMP, COVET, and our software. Next up is IDEX MultiQDX, our next paradigm cha…
  • Orlando on Monday, January 18th at 1 p.m. Eastern. We'll also make this available via live…
  • I
  • hope you can join
  • us. To
  • IDEX employees around the world, thank
  • you.
  • And a special warm welcome to our new colleagues from COVET. Your commitment to innovation…
  • IDEX. With that, I'll open the line for QA.

Speaker unclear

?If you'd like to

Passages & reports (1)
  • If you'd like to

Speaker 3

Unverified voice label

ask a question, please signal by pressing star one on your telephone keypad. If you're using a speakerphone, please make sure your mute function is off to allow your signal to reach our equipment. Once again, that is star one to signal for a question. We'll go right to Chris Schott with JP Morgan.

Passages & reports (1)
  • ask a question, please signal by pressing star one on your telephone keypad. If you're usi…

Speaker 4

Unverified voice label

Great. Thanks so much for the questions. Maybe just first on the guidance side. You started the year with about an 8% organic growth target. That number is looking now closer to 10%, and that's coming despite a vet visit environment in the U.S. that hasn't materially improved. So can you just elaborate a little bit more on what's enabling this? So, how much of this is the new platforms versus the Salesforce expansion versus maybe visits just not being the best proxy for sales growth for your business right now? ?

And
then my second question was just on the vet visit trends. ?Could you just elaborate a little bit more of what you're seeing both on the puppy side and the older dog side? I'm just trying to get a sense of where those cohorts are trending and just implications as you think about longer-term visit trends from here. Thanks so

Passages & reports (6)
  • Great. Thanks so much for the questions. Maybe just first on the guidance side. You starte…
  • bit more on what's enabling this? So, how much of this is the new platforms versus the Sal…
  • And
  • then my second question was just on the vet visit trends.
  • Could
  • you just elaborate a little bit more of what you're seeing both on the puppy side and the …

Speaker unclear

?much. Hey,

Passages & reports (1)
  • much. Hey,

Speaker 2

Chris, good morning. And uh thank thanks for the questions. This is Mike. I'll I'll speak to kind of the broader momentum in the business that gets at um several of the elements in your questions, and then Andrew will uh Andrew will rant round that out talking about um guidance and a tie back to uh some of the the trends. So as we talked about um in in the call, you know, we're we're executing exceptionally well.

Our our growth is outpacing what we're seeing in terms of broader sector averages. And Chris, this is really volume-led growth driven by the benefits that we're seeing from
our innovations, from commercial execution, and also from higher quality visits that are the result of positive trends when it comes to pet demographics. You know, on the innovation side, keep in note this is really a broad based set of benefits that we're seeing, and we're in the early stages of seeing this.

We talked about in view DX, Cancer DX, we just launched Pro B and P on Catalyst, but even pancreatic lipase, which we launched uh over two years ago, is continuing to drive incremental growth in our business. And then commercially, our teams are executing extremely well. You know, this was
a record Q3 in terms of instrument placements, and we're seeing really strong new customer growth in the labs.

And of course, all of these things come with long, durable revenue tails. So as we bring on new customers, we see the long term benefits in our growth. You know, the other thing is we're
not sitting still, of course, and neither are our customers. Uh, when we look at practices and groups who are really engaging with IDEX innovation and focusing on things like demand generation, marketing with their clients, working on the customer experience, bringing back labs clients, they're seeing growth in their businesses as well.

And we're also seeing interesting moves when it comes to how pricing is applied to things like wellness diagnostics, again, to drive demand. So the bottom line is across innovation, commercial execution, and what we're seeing in terms of aging pets. We see durable growth performance, and really our growth
doesn't rely on seeing positive visits. We can grow irrespective of that. Let me hand it over to Andrew to kind of round that out.

Passages & reports (8)
  • Chris, good morning. And uh thank thanks for the questions. This is Mike. I'll I'll speak …
  • to uh some of the the trends. So as we talked about um in in the call, you know, we're we'…
  • our innovations, from commercial execution, and also from higher quality visits that are t…
  • stages of seeing this. We talked about in view DX, Cancer DX, we just launched Pro B and P…
  • a record Q3 in terms of instrument placements, and we're seeing really strong new customer…
  • not sitting still, of course, and neither are our customers. Uh, when we look at practices…
  • well. And we're also seeing interesting moves when it comes to how pricing is applied to t…
  • doesn't rely on seeing positive visits. We can grow irrespective of that. Let me hand it o…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 1

Chris, I think to your point, you know, we've uh executed exceptionally well here. I think the initial guide that we had captured a higher end that uh they were actually above at this point, and we've been taking that up over the the course of the year. Um but you know it really comes back to a lot of the drivers that Mike highlighted here was strong execution uh really in our companion animal diagnostics uh business.

Uh the recurring growth really supported by innovation, you know, global expansion, uh, and just strong momentum, you know, given the the demand that we see for diagnostics at the clinic. Um
you know, we continue to see our our customers also be looking for ways to to grow volumes, and you know, certainly an expanded menu is one of those ways to provide better care for their clients and also grow their businesses.

And I think we find a nice matchup there. So seeing really strong
success. And I think we're comfortable with the updated guide at this point, which continues to show that we have a lot of momentum in the business, and we can continue to work through some of these pressures on clinical visits. Just in terms of your second question on the clinical visits themselves, certainly we do see some of the aging cohort continue to add uh growth within the overall makeup here while we're seeing some more muted puppy and kitten adoption levels.

That's not a new new theme. I think that's just been something that's been playing out. The macro environment continues to remain a little bit more of
a challenge, and it's something we're paying close attention to. But the positive side is the aging pet population is continuing to perform well. We see that playing through on the non wellness category more particularly. We know pets are are living longer, and I think that creates a lot of opportunity for us to continue to work with our customers on that age cohort.

Uh and then the breed mix that we see is also a positive you know tailwind for us uh over time. But you know, fundamentally the you know key drivers of the pet population, people loving their pets, uh remain intact, and I think that's
a positive story for the longer term.

Passages & reports (8)
  • Chris, I think to your point, you know, we've uh executed exceptionally well here. I think…
  • back to a lot of the drivers that Mike highlighted here was strong execution uh really in …
  • you know, we continue to see our our customers also be looking for ways to to grow volumes…
  • success. And I think we're comfortable with the updated guide at this point, which continu…
  • do see some of the aging cohort continue to add uh growth within the overall makeup here w…
  • a challenge, and it's something we're paying close attention to. But the positive side is …
  • continue to work with our customers on that age cohort. Uh and then the breed mix that we …
  • a positive story for the longer term.

Speaker 4

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

We'll move next to uh John Block with Stafel.

Passages & reports (1)
  • We'll move next to uh John Block with Stafel.

Speaker 5

Unverified voice label

Okay, great. Uh hey guys, good morning. Uh two for me, I'll I'll break them up. I guess just maybe the first one. I think the in views ?are forty six hundred year to date. Um I think you said now exceed the fifty five hundred for twenty twenty-six. But I mean also your total since inception, since the launch, seems to be um running solidly ahead of near term expectations.

Maybe you're at about eleven thousand total. Correct me if I'm if I'm
wrong there. So just how do we think about that? You know, twenty thousand analyzers over five years, with now maybe you knocking out more than a half of those within two years. Are there any changes to that uh long-term assumption? And then I'll ask the follow-up.

Passages & reports (4)
  • Okay, great. Uh hey guys, good morning. Uh two for me, I'll I'll break them up. I guess ju…
  • are
  • forty six hundred year to date. Um I think you said now exceed the fifty five hundred for …
  • wrong there. So just how do we think about that? You know, twenty thousand analyzers over …

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 2

John, good morning. Um, you know, we're really pleased with the uh the the momentum and the demand for Inview DX, really around the world. As I noted, we saw close to half our placements coming uh internationally. And uh, you do have the the numbers right? I mean, we've seen um just just tremendous execution when it comes to um placing uh in views.

um, you know, we're we're on track, as I said, to exceed our placement goal of fifty five hundred for the year and our uh five-year goal of twenty thousand placements. We're on we're on track to exceed both of those. And as I also
talked about it, we've got more happening with the platform itself. We continue to expand the menu, which brings even more clinical value to our customers.

Uh we added to the blood morphology menu with uh with nucleated RBCs and eccentricytes and uh fine needle aspirate, we know is something that's of real interest and
excitement to our our customers. And so we've opened up availability to that now broadly in North America. And every new install will now include pine needle aspirate. And we we love what that's doing, not just in terms of addressing a real need in the area of pine needle aspirates, but also opening up more access to care and expanding volume of care as we're seeing these customers doing twice as many masses.

And so we're really pleased with the overall performance and reception and level of customer customer demand. And we know that this analyzer is fulfilling a key need in the clinical arsenal for our customers around
the world.

Passages & reports (6)
  • John, good morning. Um, you know, we're really pleased with the uh the the momentum and th…
  • execution when it comes to um placing uh in views. um, you know, we're we're on track, as …
  • talked about it, we've got more happening with the platform itself. We continue to expand …
  • excitement to our our customers. And so we've opened up availability to that now broadly i…
  • more access to care and expanding volume of care as we're seeing these customers doing twi…
  • the world.

Speaker 5

That's great. That's great. Um, helpful caller. And then, Andrew, the second one for you, and ?I think it's an important one, so hopefully I can lay it out clearly. You know, the consistent 50 to 100 basis points of annual op margin expansion in the LRP. Do we have to think about anything differently for 2027 op margin expansion with the recent acquisition of COVID closing.

You obviously embedded some dilution
for 4Q26 with the OM guidance coming down. Do we have to think about that dilution for the first two to three quarters of next year as well until you lap it? And as a result, should we have more reserve 27 OM expansion assumptions embedded in our models? Thank

Passages & reports (4)
  • That's great. That's great. Um, helpful caller. And then, Andrew, the second one for you, …
  • I
  • think it's an important one, so hopefully I can lay it out clearly. You know, the consiste…
  • for 4Q26 with the OM guidance coming down. Do we have to think about that dilution for the…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Thanks, John. Appreciate the question. So as you highlighted, you know, we did include about 30 basis points of operating margin, you know, impact from the COVID acquisition really spans both Q3 and Q4. But I think from a Q4 and going forward perspective, we have factored that into the profile. I think we're still delivering on the full year operating margin results and expectations for our long term growth algorithm, even including some of that impact.

And we've been able to increase our overall guidance on revenue and EPS as it relates to those metrics
as well. So certainly as part of the deal, we have some transaction costs, some integration costs, as well as then just the overall business performance, which would include some of the impact from things like amortization of the deal as well. But keep in mind we did highlight that we expect over the next 12 months we would grow the total company revenues in line with those longer-term expectations of 50 to 100 basis points of annual operating margin uh impact here.

So as we you know get through the integration of the deal itself and we continue to see success in growing that business, we would build off
of the overall operating margin and expand the operating margins of COVID directly. But keep in mind we'd also just be managing this as a portfolio. Similar to many of our other innovations, you know, we do see multiplier benefits across this deal.

So it's both a direct revenue growth driver for the
software business itself, but we see opportunities to really expand the use of diagnostics. And so when we think about both of those components, we want to make sure we're making the right investments within the business overall. And we'd kind of look to see it play out that way. But we haven't come off of our long-term growth algorithm related to this deal directly.

And I think we have opportunity to continue to grow into 27 as

Passages & reports (7)
  • Thanks, John. Appreciate the question. So as you highlighted, you know, we did include abo…
  • factored that into the profile. I think we're still delivering on the full year operating …
  • as well. So certainly as part of the deal, we have some transaction costs, some integratio…
  • 12 months we would grow the total company revenues in line with those longer-term expectat…
  • of the overall operating margin and expand the operating margins of COVID directly. But ke…
  • software business itself, but we see opportunities to really expand the use of diagnostics…
  • of our long-term growth algorithm related to this deal directly. And I think we have oppor…

Speaker unclear

?well.

Passages & reports (1)
  • well.

Speaker 5

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Our next question comes from the line of Aaron Wright with Morgan Stanley.

Passages & reports (1)
  • Our next question comes from the line of Aaron Wright with Morgan Stanley.

Speaker 6

Unverified voice label

Great. Thanks for taking my questions. I have one follow up on the macro discussion earlier and then and then ?and then also on Rough Lab. Um so can you speak to what magnitude of sensitivity that you're baking into guidance at this point from a macro perspective? I guess did you see any shift in that demand trends throughout the quarter? I'm just trying to get gauge in terms of you mentioned for instance that you're continuing to monitor what you're seeing out there from a macro perspective and just given that innovation obviously allows you to grow through this?

How are you thinking about the macro in the context of launching a new instrument next year and or multi-que when you do launch it? Do you think vets are
in a position to invest invest further in innovation? How will multi-queue, for instance, address some of those pain points at the clinic level? And then just a quick one on Ref Lab, you had another double digit growth quarter in Ref Lab, which tends to be a little bit more tied to vet office visits. ?

So, you
know, how much of that is attributable to market share gains versus just greater utilization per existing customer given the innovations? Thanks.

Passages & reports (8)
  • Great. Thanks for taking my questions. I have one follow up on the macro discussion earlie…
  • and
  • then also on Rough Lab. Um so can you speak to what magnitude of sensitivity that you're b…
  • you're continuing to monitor what you're seeing out there from a macro perspective and jus…
  • in a position to invest invest further in innovation? How will multi-queue, for instance, …
  • visits.
  • So, you
  • know, how much of that is attributable to market share gains versus just greater utilizati…

Speaker 1

Thanks. Good morning, Aaron. Maybe I'll address the the first question and then Mike can you know talk about our reference lab growth profile.

Passages & reports (1)
  • Thanks. Good morning, Aaron. Maybe I'll address the the first question and then Mike can y…

Questions & answers

Speaker unclear

?You

Passages & reports (1)
  • You

Speaker 1

know, just from a macro perspective, I think you know it's been relatively consistent for us. You know, I think you know in terms of what we see play out on clinical visits, certainly macro does have an impact here. Yeah, I think when you look at the overall guide and what we've included in there, you know, it is a range, uh, but you know, we've really had you know consistent trends here more recently and you know really in line with our our prior guide estimates as well.

So um not a lot of uh change, you know, just in terms of that uh expectation as we head
into at this point. Um, you know, keep in mind it can be a little bit you know choppy quarter to quarter, you know, variability um, you know, just with the overall metric itself. But uh yeah, I think we've captured that. What we're really excited by is the you know continued quality of the visits, and that's really what we're focused on is driving that quality.

And by quality we mean you know broadening the use of diagnostics, you know, using diagnostics more frequently in the pets that are coming through the door. And both of those metrics remain solid and we continue to engage with our customers to
look for ways for them to grow overall volumes. That's really our key focus at this point strategically and I think we're seeing a lot of success in that.

But maybe I'll have Mike talk about the reference lab piece of this.

Passages & reports (5)
  • know, just from a macro perspective, I think you know it's been relatively consistent for …
  • there, you know, it is a range, uh, but you know, we've really had you know consistent tre…
  • into at this point. Um, you know, keep in mind it can be a little bit you know choppy quar…
  • visits, and that's really what we're focused on is driving that quality. And by quality we…
  • look for ways for them to grow overall volumes. That's really our key focus at this point …

Speaker unclear

?Yeah

Passages & reports (1)
  • Yeah

Speaker 2

good morning Aaron. Hey we've been really um really uh pleased with uh the high growth in the reference labs around the world, by the way. It's really a global um you know set of performance metrics that we're looking at there. And this this is the outcome of investments that we've made over many, many years into really all aspects of the lab experience, certainly the investments that we've made into to networks so we can provide a very strong local service experience to customers uh all around the world.

And that's something we continue to invest in to expand that network and make sure that we're getting closer
to customers and we can serve them in in a really uh really strong way. Uh and then technology, uh, you know, the backbone of technology in our reference labs is very sophisticated and allows us to provide, again, a great level of service, but also the the types of sophisticated diagnostics that we that we run, and then innovation in terms of you know various tests.

And that's broad based as well. I mean, we talk a lot about Cancer DX, and that's certainly been a very strong uh uh driver of lab growth. Um you know we're seeing, for example, still upwards of 20 plus percent of cancer
DX runs coming from customers that aren't primarily using the IDEX reference labs. And those are opportunities for those customers to experience our lab value proposition and that opens up the door to a conversation and we're seeing, you know, as we shared, really strong new customer growth that is, you know, in part an out an outcome of of that kind of conversation.

But we're also you know investing in other areas. We added Tania tapeworms for example to our fecal DX DX antigen panel in the reference lab. So it's really a broad-based innovation strategy that includes Cancer DX and other areas along with the kind of service
experience that we're we're providing. And we're doing this around the world. So we're really, really pleased to see the growth in the lab, not just in the US, but also internationally as we engage with customers, you know, not just in one modality, but in this total solution approach that includes point of care diagnostics, reference labs, and uh and software in an even expanded

Passages & reports (8)
  • good morning Aaron. Hey we've been really um really uh pleased with uh the high growth in …
  • many years into really all aspects of the lab experience, certainly the investments that w…
  • to customers and we can serve them in in a really uh really strong way. Uh and then techno…
  • we run, and then innovation in terms of you know various tests. And that's broad based as …
  • DX runs coming from customers that aren't primarily using the IDEX reference labs. And tho…
  • out an outcome of of that kind of conversation. But we're also you know investing in other…
  • experience that we're we're providing. And we're doing this around the world. So we're rea…
  • diagnostics, reference labs, and uh and software in an even expanded

Speaker unclear

?way.

Passages & reports (1)
  • way.

Speaker 3

Once again, if you'd like to signal for a question that star one will go next to Matt Delator with Goldman Sachs.

Passages & reports (1)
  • Once again, if you'd like to signal for a question that star one will go next to Matt Dela…

Speaker unclear

?Great.

Passages & reports (1)
  • Great.

Speaker 7

Unverified voice label

Thanks for the question

Passages & reports (1)
  • Thanks for the question

Speaker unclear

?and congrats on the quarter. Maybe first

Passages & reports (1)
  • and congrats on the quarter. Maybe first

Speaker 1

going back to NDDX, could you provide a bit more color on just what drove the strong placements in the quarter? Specifically, you know, any notable trends you're seeing with regard to to update or how clinics are are utilizing the product across ear, blood, or FNA. And then maybe looking ahead to the upcoming VMX event for multi-q, could you just give us an idea of maybe what you'll you'll share with that disclosure and then how do you think about the actual launch timing on the back of that?

Thanks very

Passages & reports (2)
  • going back to NDDX, could you provide a bit more color on just what drove the strong place…
  • VMX event for multi-q, could you just give us an idea of maybe what you'll you'll share wi…

Speaker unclear

?much. Hey,

Passages & reports (1)
  • much. Hey,

Speaker 2

good morning, and thanks for the question. ?You know, just coming back on the first part of your question for MVUDX, you know, really it's it's it's you you look at the instrument and the critical need that it's addressing around cytology. I mean psychology is uh a a category of diagnostics that's practiced you know virtually in every practice around the world. They all have a microscope and it's been done the same way for over a hundred years in a highly manual fashion.

It requires a lot of steps. It's pretty messy and it's technique sensitive. And so in view DX addresses that core need. It it takes out the slide which is a revolutionary step.

Passages & reports (4)
  • good morning, and thanks for the question.
  • You
  • know, just coming back on the first part of your question for MVUDX, you know, really it's…
  • They all have a microscope and it's been done the same way for over a hundred years in a h…

It's got advanced optics and AI and so it's filling a key need. And that's really, I think, at the core of it. Certainly if we've as we've added to the capabilities on the instrument, you know, that uh makes it even more clinically valuable. And I think one of the things that customers have come to appreciate about IDEX is that we never stand still.

We're constantly expanding the value of these platforms. And so you know this year alone, we've added you know like over half a dozen new things to our our blood morphology menu just for example and two just in the in the last quarter.

Passages & reports (2)
  • It's got advanced optics and AI and so it's filling a key need. And that's really, I think…
  • come to appreciate about IDEX is that we never stand still. We're constantly expanding the…

And we continue to expand and fine needle Ashbird is really early in that part of the innovation journey for NVUDX. So I think there's a lot of exciting menu and kind of roadmap ahead of us. We've seen strong placements around the world too, as we noticed internationally. That accounted for almost half the placement. So as we've expanded availability of NVUDX globally, we've seen really good demand and uptake there.

And so I just think this is really it's filling the key need with our customers, and that's what's generating demand. And certainly we have really strong commercial teams that are able to engage with customers and support
that demand through our commercial execution and and that's resulting in the the types of numbers that that we've shared. You know with respect to um our events at Orlando and Multi QDX we'll talk more about Multi QDX there.

We're not providing more information today but we're certainly excited about it and I hope
you can join us at at the uh at the event

Passages & reports (4)
  • And we continue to expand and fine needle Ashbird is really early in that part of the inno…
  • placement. So as we've expanded availability of NVUDX globally, we've seen really good dem…
  • that demand through our commercial execution and and that's resulting in the the types of …
  • you can join us at at the uh at the event

Speaker 7

great thank you

Passages & reports (1)
  • great thank you

Speaker unclear

?both

Passages & reports (1)
  • both

Speaker 3

we go next to Stephen Deckert with Key Bank Capital Markets.

Passages & reports (1)
  • we go next to Stephen Deckert with Key Bank Capital Markets.

Speaker unclear

?Hey, thanks for the question, guys. I

Passages & reports (1)
  • Hey, thanks for the question, guys. I

Speaker 7

guess, first off, um, ?I know you've given the cumulative number of clinics that have ordered Cancer DX to date since it's launching. Just anything on what number of those clinics are are recurring? Thanks.

Passages & reports (3)
  • guess, first off, um,
  • I
  • know you've given the cumulative number of clinics that have ordered Cancer DX to date sin…

Speaker 2

Hi. Yeah, we uh good morning. Thanks. Thanks for the Cancer DX question. You know, this Cancer DX is really proving to be one of the most consequential innovations in the history of the company. I mean, this is a category that has just been calling out for innovation. It's, you know, you look at one out of four dogs being diagnosed with cancer in their lifetime, and there really has been no solution for early and specific detection ?of cancer.

So Cancer DX is filling a key need, and we're seeing just a lot of excitement and interest in what it can do in the practice.
?You know, we've we've shared some numbers around customer growth. We we saw again significant expansion in that. We're at over 14,000 customers having uh uh ordered and run Cancer DX. We don't split that out further, but I can tell you that we're seeing really great uh momentum and demand, and also, as I shared, uh really good multiplier benefits into broader diagnostics utilization, with 70% of Cancer DX runs being together with the blood work panel in our reference lab.

So we're we're very happy with the momentum, and and I would say it's still early days. There's a lot of opportunity ahead of us as we continue to
build out the panel and address this key area of clinical need for dogs.

Passages & reports (8)
  • Hi. Yeah, we uh good morning. Thanks. Thanks for the Cancer DX question. You know, this Ca…
  • one out of four dogs being diagnosed with cancer in their lifetime, and there really has b…
  • of
  • cancer. So Cancer DX is filling a key need, and we're seeing just a lot of excitement and …
  • You
  • know, we've we've shared some numbers around customer growth. We we saw again significant …
  • uh really good multiplier benefits into broader diagnostics utilization, with 70% of Cance…
  • build out the panel and address this key area of clinical need for dogs.

Speaker 7

Great.

Passages & reports (1)
  • Great.

Speaker 3

Our next question comes from Daniel Clark with Learning Partners.

Passages & reports (1)
  • Our next question comes from Daniel Clark with Learning Partners.

Speaker unclear

?Great, thanks so much, and good morning. Why did I

Passages & reports (1)
  • Great, thanks so much, and good morning. Why did I

Speaker 3

first ask about the NV

Passages & reports (1)
  • first ask about the NV

Speaker unclear

?revenue for analyzer

Passages & reports (1)
  • revenue for analyzer

Speaker 1

given it's already in your $3,500 to $5,500

Passages & reports (1)
  • given it's already in your $3,500 to $5,500

Speaker unclear

?per you know per year

Passages & reports (1)
  • per you know per year

Speaker 1

range? Like how are you thinking about that trending over time given in view FA is just rolling out, and that feels like an area with you know significant unmet

Passages & reports (1)
  • range? Like how are you thinking about that trending over time given in view FA is just ro…

Speaker unclear

?need?

Passages & reports (1)
  • need?

Speaker 2

Hey, thanks for the question. Um so we're we're comfortably in the range of the 3,500 to 5,500 uh annual recurring revenue per instrument that we've shared in the past. And this range, keep in mind, uh encompassed uh both your cytology, blood morphology, and also fine needle aspirate. You know, most customers, as we rolled out blood morphology and ear cytology, do both. Those are really complementary care episodes and areas, kind of submodalities, if you will, within cytology.

And we expect the same will be true as we roll out
?a pine needle aspirate more broadly. And so, you know, as we do roll out finedal aspirate, we certainly see additional upside there to drive growth, balanced out by the fact that we continue to broaden availability of the of the instrument around the world. And so the range is meant to encompass various practice sizes as we go more international and all of those things kind of factor into that.

So we see long-term opportunity here. And we're not done with the menu on NVUDX. I mean, we can look uh around the corner and see a hundred million uh more cytology tests being done around the world in a
you know, frankly, manual and um suboptimal way. And so we are really excited about the long-term opportunity to continue to advance this platform and meet more and more of the needs and cytology in the practice.

Passages & reports (6)
  • Hey, thanks for the question. Um so we're we're comfortably in the range of the 3,500 to 5…
  • needle aspirate. You know, most customers, as we rolled out blood morphology and ear cytol…
  • a
  • pine needle aspirate more broadly. And so, you know, as we do roll out finedal aspirate, w…
  • as we go more international and all of those things kind of factor into that. So we see lo…
  • you know, frankly, manual and um suboptimal way. And so we are really excited about the lo…

Speaker unclear

?Got

Passages & reports (1)
  • Got

Speaker 7

it super helpful. And then just a quick follow-up, you know, on the incremental placement opportunity from here, obviously international has been quite strong. US has been a little more stable. So how are you thinking about incremental uptake from here? Is this more of a worldwide launch at this point? Um and maybe where we are in terms of you know innings for both would be great.

Thank

Passages & reports (2)
  • it super helpful. And then just a quick follow-up, you know, on the incremental placement …
  • we are in terms of you know innings for both would be great. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Yeah, we're we're in full worldwide launch mode within BUDX. And um and so we we see uh you know really meaningful headroom to continue to place instruments around the

Passages & reports (1)
  • Yeah, we're we're in full worldwide launch mode within BUDX. And um and so we we see uh yo…

Speaker unclear

?world.

Passages & reports (1)
  • world.

Speaker 3

We'll take our next question from Nivon Tai with BMP Parabal.

Passages & reports (1)
  • We'll take our next question from Nivon Tai with BMP Parabal.

Speaker unclear

?Hi, thank

Passages & reports (1)
  • Hi, thank

Speaker 3

you ?for taking my question. Um ?I had a ?question on pricing, whether you expect pricing in the animal health diagnostics sector to remain resilient versus um the animal health pharma. Um, As we know that the therapeutic market leader has announced pricing action. Do you think diagnostics are isolated? And do you expect that to continue for IDEC? Thank

Passages & reports (8)
  • you
  • for
  • taking my question. Um
  • I
  • had a
  • question on pricing,
  • whether you expect pricing in the animal health diagnostics sector to remain resilient ver…
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Good morning, Nabon. Thanks for the question. You know, we I don't know that I'll comment on pricing in the in the pharmaceutical area. You know, in our area, we certainly know that it's a competitive sector as it's always been. You know, we focus on price as a as a measure of the value that we're creating. We're very transparent around how price factors into our overall growth formula, you know, both in the past and going forward.

And you know, we put a lot of focus on making sure that when we put forward pricing, it's consistent with the value that we're providing. And then, as we've shared,
you know, a major part of our strategy also, if you look at what we're doing with cancer DX, for example, $15 for in the US and an equivalent number around the world for Cancer DX when it's run as a screening test together with blood work in our lab.

You know, this is just
an example of what we're doing to make a bold statement around affordable screening so that more pets have access to care. And what we see is that also drives more volume of care. And this is absolutely turning heads with our customers. They really welcome our stance on this. You know, I've shared in the past we've had a large corporate group that went all in with Cancer DX as part of their senior dog wellness program and they're seeing higher utilization, higher enrollments.

It's driving their broader wellness business.
?You know, I was with a practice, an independent practice down in the southern part of the U.S. and they went all in with cancer DX for all senior dogs, and they're seeing uh up in the high 30s in terms of wellness blood work inclusion in their practice. So, you know, we know the the strategy works. We want to make sure it's an accessible strategy so that doctors ?and owners aren't having to make this false choice between blood work screening, blood work, uh, you know, running the blood work and finding out if their dog has cancer and that's you know that that strategy is working.

Passages & reports (10)
  • Good morning, Nabon. Thanks for the question. You know, we I don't know that I'll comment …
  • that we're creating. We're very transparent around how price factors into our overall grow…
  • you know, a major part of our strategy also, if you look at what we're doing with cancer D…
  • an example of what we're doing to make a bold statement around affordable screening so tha…
  • the past we've had a large corporate group that went all in with Cancer DX as part of thei…
  • You
  • know, I was with a practice, an independent practice down in the southern part of the U.S.…
  • strategy works. We want to make sure it's an accessible strategy so that doctors
  • and
  • owners aren't having to make this false choice between blood work screening, blood work, u…

Speaker 1

And just related to the uh overall company, we've had very consistent pricing, you know, starting with our initial guidance and we've continued to update folks uh along the way about that, which really hasn't changed, you know, in terms of our expectations. Yeah, to Mike's point, we we're constantly focused on you know value. Um we're not looking to to maximize price. Uh you know we're really trying to you know expand the sector you know through volume.

Um but you know we've been very consistent in terms of uh expectations that we have set early in the part of the

Passages & reports (2)
  • And just related to the uh overall company, we've had very consistent pricing, you know, s…
  • Um we're not looking to to maximize price. Uh you know we're really trying to you know exp…

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 3

Thank you, both. And maybe just a quick one. If you have any early feedback on the mast cell tumor edition that was launched in September, thank

Passages & reports (1)
  • Thank you, both. And maybe just a quick one. If you have any early feedback on the mast ce…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Yeah, that that is just getting really, really positive feedback. You know, we're early in the launch process to be clear. Um, but certainly customers really welcome the fact that Cancer DX has now turned the corner from a test to a multi-cancer panel. And mast cell tumor is is one of the most common cancers in dogs and it it often gets missed. It can be, especially with dogs that have longer coats, it can be really hard to find mast cell tumors.

And the connection between cancer DX and invx is also really exciting. When you get a positive on cancer DX, and if you have uh lumps
and bumps and masses, you want to go find out which one of those is is cancerous. And that's where invx is a natural next step there. So we're seeing really high receptivity to uh mast cell tumor and a lot of excitement too around hemangiosarcoma, which is coming next.

Passages & reports (3)
  • Yeah, that that is just getting really, really positive feedback. You know, we're early in…
  • cancers in dogs and it it often gets missed. It can be, especially with dogs that have lon…
  • and bumps and masses, you want to go find out which one of those is is cancerous. And that…

Okay, so with that, I want to thank uh all of you for your questions. We'll now conclude the QA portion of this morning's call. It's a pleasure to share IDEX's continued execution against our innovation-driven growth strategy while delivering strong financial results in the quarter. Thank you for your participation and we'll now conclude the call.

Passages & reports (2)
  • Okay, so with that, I want to thank uh all of you for your questions. We'll now conclude t…
  • the call.
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 100. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T03:47:39.679Z.
Transcript version v1-790d7a514c765cd8b5ab · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.